Promising long-term results for combination immunotherapy for advanced melanoma

The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results Рlong-lasting with high survival rates Рresearchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, presented the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.Continue reading